Correction to: Blood Cancer Journal
https://doi.org/10.1038/s41408-020-00342-x published online 24 July 2020
The original version of the article contained an error in Fig. 1b, which showed that 57/69 (78.3%) of patients with CR in the first 2 cycles achieved MRD response. The article has now been corrected to state 57/69 (82.6%).
Fig. 1
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Locatelli, F., Zugmaier, G., Mergen, N. et al. Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 11, 28 (2021). https://doi.org/10.1038/s41408-021-00413-7
Published:
DOI: https://doi.org/10.1038/s41408-021-00413-7
